Learn More
Inhalation Innovation: Phase IIb Study Design of Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis Martin Kolb, Colin Reisner, Deepthi Nair, Felix Woodhead, Howard Lazarus, Craig Conoscenti
Association between Functional Improvement and Structural Changes in Quantitative High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis Grace Kim, Jonathan Goldin, Deepthi K. Nair, Felix A. Woodhead, Craig Conoscenti, Howard M. Lazarus
Correlation of Early Cough with Disease Activity measured by High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis Grace Kim, Jonathan Goldin, Felix A. Woodhead, Deepthi K. Nair, Howard M. Lazarus, Craig Conoscenti
Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis Nazia Chaudhuri, Barnaby Hirons, Felix A. Woodhead, Allison Trucillo, Hao Bao, Deepthi K. Nair, Colin Reisner, Andrey Pavlov, Craig Conoscenti, Howard M. Lazarus, Surinder Birring
Inhalation Innovation: Phase 2b Study Design on Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis Martin Kolb, Colin Reisner, Deepthi K. Nair, Felix A. Woodhead, Howard M. Lazarus, Craig Conoscenti
Safety and efficacy of inhaled pirfenidone (AP01) in the ATLAS open-label extension study Margaret L. Wilsher, Felix A. Woodhead, Deepthi K. Nair, Hao Bao, Howard M. Lazarus, Tamera J. Corte
Differences in e-Lung biomarker scores between treatment groups in post-hoc analysis of the ATLAS inhaled pirfenidone solution (AP01) for IPF clinical trial Peter M. George, et al.
Inhaled pirfenidone reduces the risk of disease progression: a post-hoc analysis of the ATLAS study Lancaster LH, Lazarus HM, Woodhead FA, Nair DK, Pavlov A, Reisner C, Nathan SD
Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients Woodhead FA, Nair D, Bao H, et al. (2023) Poster presented at Pulmonary Fibrosis Foundation (PFF) Summit
Improvement in HRCT Lung Fibrosis with Inhaled Pirfenidone Is Associated with Better Health-Related Quality of Life Scores in Patients with Idiopathic Pulmonary Fibrosis Woodhead FA, Kim GHJ, Goldin JG, et al. (2023) Poster presented at Pulmonary Fibrosis Foundation (PFF) Summit
Inhaled pirfenidone (AP01) forced vital capacity (FVC) data from the ATLAS study vs placebo from 3 historical idiopathic pulmonary fibrosis (IPF) randomised controlled trials (RCTs) Chaudhuri N, Lancaster L, Palmer S, et al. (2023) poster presented at European Respiratory Society (ERS) International Congress
Nebulised Pirfenidone in Non-Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis (PPF): First Look at FVC Data West A, Lawrence A, Bao H, et al (2023) poster presented at European Respiratory Society (ERS) International Congress
Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients Woodhead FA, Nair D, Bao H, et al. (2023) ePoster presented at American Thoracic Society (ATS) International Conference
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial West A, Chaudhuri N, Barczyk A, et al. (2023) Thorax
Inhaled Pirfenidone Is Associated With Better Quality of Life Scores in Idiopathic Pulmonary Fibrosis Kim G, Goldin J, Woodhead F, et al. (2022) European Respiratory Journal
Improvement in HRCT Lung Fibrosis With Inhaled Pirfenidone Is Associated With Better Health-Related Quality of Life Scores in Patients With IPF Woodhead FA, Kim GHJ, Goldin JG, et al. (2022) poster presented at the European Respiratory Society (ERS) International Congress
A Randomized Double-Blind Placebo-Controlled Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Khoo JK, Montgomery AB, Otto KL, et al. (2018) Journal of Aerosol Medicine and Pulmonary Drug Delivery
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis Kaminskas LK, Landersdorfer CB, Bischof RJ, et al. (2020) Pharmaceutical Research
Pharmacokinetics and Safety of Pirfenidone Following Inhaled Delivery to Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis Surber M, Kaminskas L, Landersdorfer C, et al. (2019) poster presented at American Thoracic Society (ATS) International Conference
Fibroblast–matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype Shochet GE, Wollin L & Shitrit D. (2018) Asian Pacific Society of Respirology
Inhalation Improves Pirfenidone Animal Efficacy Through Superior Pulmonary and Vascular Pharmacokinetics Surber MW, Poulin D, McInally K, et al. (2014) poster presented at American Thoracic Society (ATS) International Conference
Inhaled Nintedanib: Predictive Sheep Model for Human Dose Selection and Tolerability Surber MW, Pham S, Bischof R. (2023) Poster presented at Pulmonary Fibrosis Foundation (PFF) Summit
Nebulised Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF): First Look at FVC Data West A, Lawrence A, Bao H, et al. (2023) oral presentation given at European Respiratory Society (ERS) International Congress
Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis Shochet GE, Bardenstein-Wald B, McElroy M, et al (2021). International Journal of Molecular Science
Inhaled Nintedanib Is Well-Tolerated and Delivers Key Pharmacokinetic Parameters Required To Treat Bleomycin-Induced Pulmonary Fibrosis Surber MW, Beck S, Pham S, et al. (2020) Pulmonary Pharmacology
Inhalation: A Means to Explore and Optimize Nintedanib’s Pharmacokinetic/codynamic Relationship Shochet GE, Pham S, Beck S, et al. (2020) Pulmonary Pharmacology
Direct Lung Administration of Nintedanib Reduces Lung Fibrosis in a Multi-Challenge Bleomycin Rat Model McElroy MC, Beck S, Baily J, et al. (2020) poster presented at American Thoracic Society (ATS) International Conference
Inhalation: A Means to Improve Existing IPF Therapies Surber MW, Montgomery AB, Otto K, et al. (2022)
Assessment of Regional Lung Deposition of Aerosol Aerodone in IPF Patients Using Functional Respiratory Imaging Vos W, Van Holsbeke C, Ferreira F, et al. (2015) poster presented at Pulmonary Fibrosis Foundation Summit: From Bench to Bedside